Urinary Proteomics Analysis for Sepsis and Prognosis

• Conditions: SIRS; Sepsis

• Registration Number: NCT01493492
• Lead Sponsor: Chinese PLA General Hospital

Brief Summary

As a noninvasive examination, urinary proteomics is a very useful tool to identify renal disease. The purpose of the present study was to find differential proteins among patient with SIRS and sepsis(included survivors and non-survivors), and to screen potential biomarkers for the early diagnosis of sepsis and its prognosis. Urinary proteins were identified by iTRAQ labeling and LC-MS/MS. The bioinformatics analysis was performed with the Mascot software and the International Protein Index (IPI) and the Gene Ontology (GO) Database and KEGG pathway Database. The differentially expressed proteins were verified by Western blot by another sample collected from clinical.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-05
• Status Verified: 2011-12
• Study First Submitted: 2011-12-14
• Study First Submitted QC: 2011-12-15
• Last Update Submitted: 2011-12-15
• Study First Posted: 2011-12-16
• Last Update Posted: 2011-12-16
• Primary Completion: 2012-01
• Study Completion: 2012-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Male and female aged 18 years old and over;
• clinically confirmed infection;
• fulfilled at least two criteria of systemic inflammatory response syndrome
• (a) core temperature higher than 38 °C or lower than 36 °C
• (b)respiratory rate above 20/min, or PCO2 below 32 mmHg
• (c) pulse rate above 90/min, and
• (d) white blood cell count greater than 12,000/μl or lower than < 4,000/μl or less than 10% of bands.

Exclusion Criteria

• younger than 18 years of age;
• acquired immunodeficiency syndrome;
• reduced polymorphonuclear granulocyte counts (< 500 μL-1);
• died within 24h after admission into the ICU, or refused to participate in the study, or declined treatment during the period of observation.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Survival status	28days after admited in ICU	The survival time of patients more than 28days is defined as survival. The survival time of patients less than 28days is defined as death

Trial Locations

Locations (1)

Chinese PLA General Hospital; 🇨🇳 Beijing, Beijing, China